Engaging Broader Stakeholders to Accelerate Group A Streptococcus Vaccine Development

Area of Science:

• Infectious Diseases
• Vaccinology
• Microbiology

Background:

• Group A Streptococcus (GAS) causes over 600 million pharyngitis cases and 18 million severe infections annually, posing a significant global health burden.
• Recent outbreaks of scarlet fever and streptococcal toxic shock syndrome (STSS) highlight the urgent need for effective GAS interventions.
• Currently, no licensed vaccine against GAS is available for clinical use.

Purpose of the Study:

• To provide a comprehensive review of the developmental history of Group A Streptococcus (GAS) vaccines.
• To systematically analyze clinical trial outcomes and recent advances in GAS vaccine candidates.
• To identify critical strategies for accelerating the commercialization and availability of GAS vaccines.

Main Methods:

• Review of historical and contemporary GAS vaccine development, including inactivated, multivalent, conjugate, multi-antigen, and mRNA platforms.
• Systematic analysis of clinical trial data for various GAS vaccine candidates.
• Evaluation of promising target antigens, including M protein-based and non-M protein approaches.

Main Results:

• The review traces the evolution of GAS vaccine research from early attempts to modern platforms.
• Analysis of clinical trials reveals progress and challenges in developing effective GAS vaccines.
• Promising target antigens and innovative vaccine technologies are identified.

Conclusions:

• Accelerating GAS vaccine development requires enhanced R&D investment, expanded collaborations, and advanced technologies.
• Streamlined clinical trials and strengthened public health advocacy are essential for timely vaccine commercialization.
• Engaging broader stakeholders is critical to expedite the availability of a much-needed GAS vaccine.